Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Cyramza® (ramucirumab): Preparation and concentration range
Prepare as directed below using aseptic technique and sterile sodium chloride (0.9%) solution as a diluent to achieve a final volume of 250 mL in the concentration range 0.4 to 4.0 mg/mL.
Prepare the infusion solution using an aseptic technique to ensure the sterility of the prepared solution.1
Each vial of ramucirumab is intended for single use only.1
- Inspect the contents of the vials for particles and discolouration before dilution. The colour should be clear to slightly opalescent and colourless to slightly yellow without visible particles. If particles or discolourations are identified, discard the vial.
- Calculate the dose and the required volume of ramucirumab needed to prepare the infusion solution. Vials contain either 100 mg or 500 mg as a 10 mg/ml solution of ramucirumab. Only use sodium chloride 9 mg/ml (0.9%) solution for injection as a diluent.
- Dilute ramucirumab as required to achieve a final volume of 250 mL. Only use sterile sodium chloride (0.9%) solution for injection as a diluent.
- In case of prefilled intravenous (IV) infusion container usage: based on the calculated volume of ramucirumab, remove the corresponding volume of sterile sodium chloride (0.9%) solution for injection from the prefilled 250-mL IV container. Aseptically transfer the calculated volume of ramucirumab to the IV container. The final total volume in the container should be 250 mL.
- In case of empty IV infusion container usage: aseptically transfer the calculated volume of ramucirumab into an empty IV container. Add a sufficient quantity of sterile sodium chloride (0.9%) solution for injection to the container to make the total volume 250 mL.
- The container should be gently inverted to ensure adequate mixing.
- Do not freeze or shake the infusion solution.
- Do not dilute with other solutions or co-infuse with other electrolytes or medication.
- Parenteral drug products should be inspected visually for particles before administration. If particles are identified, discard the infusion solution.
- Discard any unused portion of ramucirumab left in a vial, as the product contains no preservatives.1,2
Additional information on final volume and concentration range
Eli Lilly and Co. does not have specific data to support diluting ramucirumab to concentrations below 0.4 mg/mL (ie, 10 mL of the 100 mg/10mL vial diluted with sodium chloride [0.9%] solution for injection to a final volume of 250 mL).
The concentration of ramucirumab in the prepared dose must be within 0.4 to 4.0 mg/mL. Larger containers (ie, 500 ml) of sodium chloride (0.9%) solution for injection may be used if adjusted to the target dose volume of 250 mL and the concentration of ramucirumab in the prepared dose is within 0.4 to 4.0 mg/mL.1
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Cyramza [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 24 March 2022